Cantor Fitzgerald Brokers Reduce Earnings Estimates for MDGL

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of Madrigal Pharmaceuticals in a report released on Wednesday, November 5th. Cantor Fitzgerald analyst P. Agrawal now expects that the biopharmaceutical company will post earnings of ($9.43) per share for the year, down from their prior forecast of ($5.86). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.47) per share. Cantor Fitzgerald also issued estimates for Madrigal Pharmaceuticals’ FY2026 earnings at $8.12 EPS.

Several other equities analysts also recently commented on the company. JMP Securities set a $527.00 price objective on Madrigal Pharmaceuticals in a research note on Wednesday. Canaccord Genuity Group boosted their target price on Madrigal Pharmaceuticals from $428.00 to $526.00 and gave the company a “buy” rating in a research note on Friday, September 12th. TD Cowen upped their price target on Madrigal Pharmaceuticals from $390.00 to $554.00 and gave the company a “buy” rating in a research report on Tuesday, August 26th. Cowen reissued a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Tuesday, August 26th. Finally, UBS Group restated a “buy” rating and issued a $523.00 price objective (up from $458.00) on shares of Madrigal Pharmaceuticals in a research note on Tuesday, August 12th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Madrigal Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $528.42.

Madrigal Pharmaceuticals Stock Up 2.7%

MDGL opened at $488.58 on Friday. The company’s 50-day moving average price is $436.11 and its two-hundred day moving average price is $356.34. The company has a quick ratio of 4.78, a current ratio of 5.11 and a debt-to-equity ratio of 0.17. Madrigal Pharmaceuticals has a twelve month low of $265.00 and a twelve month high of $496.98. The stock has a market cap of $10.85 billion, a price-to-earnings ratio of -38.02 and a beta of -1.04.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share for the quarter, missing the consensus estimate of ($2.01) by ($3.07). The company had revenue of $287.27 million for the quarter, compared to the consensus estimate of $244.33 million. Madrigal Pharmaceuticals had a negative net margin of 54.68% and a negative return on equity of 38.38%.

Insider Transactions at Madrigal Pharmaceuticals

In other news, Director Paul A. Friedman sold 129,172 shares of Madrigal Pharmaceuticals stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $370.24, for a total value of $47,824,641.28. Following the completion of the transaction, the director directly owned 187,164 shares in the company, valued at approximately $69,295,599.36. The trade was a 40.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kenneth Bate sold 10,000 shares of the stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $365.20, for a total value of $3,652,000.00. Following the sale, the director directly owned 2,627 shares in the company, valued at $959,380.40. This trade represents a 79.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders purchased 165,683 shares of company stock valued at $61,921,142 and sold 248,642 shares valued at $91,388,103. Insiders own 21.50% of the company’s stock.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

A number of large investors have recently modified their holdings of MDGL. China Universal Asset Management Co. Ltd. grew its stake in Madrigal Pharmaceuticals by 0.7% during the second quarter. China Universal Asset Management Co. Ltd. now owns 4,459 shares of the biopharmaceutical company’s stock valued at $1,349,000 after acquiring an additional 30 shares in the last quarter. Mutual of America Capital Management LLC boosted its holdings in Madrigal Pharmaceuticals by 0.3% in the 1st quarter. Mutual of America Capital Management LLC now owns 11,263 shares of the biopharmaceutical company’s stock valued at $3,731,000 after purchasing an additional 31 shares during the period. Park Avenue Securities LLC increased its holdings in shares of Madrigal Pharmaceuticals by 6.6% in the second quarter. Park Avenue Securities LLC now owns 699 shares of the biopharmaceutical company’s stock worth $212,000 after purchasing an additional 43 shares during the period. Orion Porfolio Solutions LLC raised its position in shares of Madrigal Pharmaceuticals by 1.3% in the second quarter. Orion Porfolio Solutions LLC now owns 3,638 shares of the biopharmaceutical company’s stock worth $1,101,000 after buying an additional 47 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in shares of Madrigal Pharmaceuticals by 114.3% in the third quarter. GAMMA Investing LLC now owns 90 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 48 shares in the last quarter. 98.50% of the stock is currently owned by institutional investors.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.